Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Dec;94(6):693-7.
doi: 10.1007/BF00206965.

Genetic heterogeneity of Crigler-Najjar syndrome type I: a study of 14 cases

Affiliations

Genetic heterogeneity of Crigler-Najjar syndrome type I: a study of 14 cases

P Labrune et al. Hum Genet. 1994 Dec.

Abstract

Crigler-Najjar syndrome type I (CN-I) is an autosomal recessive condition characterized by severe unconjugated hyperbilirubinemia caused by the lack of bilirubin-UDP-glucuronosyltransferase (B-UGT) activity in the liver. Two B-UGTs are coded for by a gene complex (UGT1) that maps to chromosome 2q37 and that also encodes two phenol-UDP-glucuronosyltransferases. Here, we report eleven mutations (including nine novel mutations) of the B-UGT1 gene in a large series of 14 unrelated CN-I children of various geographic origins: France (seven patients: A401P, Q357X, W335X, A368T, 1223insG, A291V, K426E, K437X); Portugal (two patients: G308E); Tunisia (two patients; Q357R); Turkey (one patient: S381R); italy (two siblings: S381R). Interestingly, 6/14 mutant alleles carried by unrelated probands of French ancestry bore the A401P mutation, indicating a founder effect; this effect is probably also present in Portugal, Turkey, and Tunisia. Since mutations occurred in exons 2-5 shared by all mRNAs species of the gene, a combined deficiency of B-UGT and P-UGT was observed in the liver of five patients in whom these activities were measured. The present study confirms that CN-I is genetically heterogeneous and suggests that different founder effects are involved in Western Europe, the Middle East, and North Africa.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Hepatology. 1992 Mar;15(3):532-44 - PubMed
    1. FASEB J. 1992 Jul;6(10):2859-63 - PubMed
    1. Pediatrics. 1952 Aug;10(2):169-80 - PubMed
    1. Biochem Pharmacol. 1983 Mar 15;32(6):953-5 - PubMed
    1. Biochem Biophys Res Commun. 1993 Dec 30;197(3):1239-44 - PubMed

Publication types

LinkOut - more resources